CD30 - the head of TNF-family… or a successful story of brentuximab vedotin

Q4 Medicine

Archive of Oncology Pub Date : 2013-01-01 DOI:10.2298/AOO1301017P

L. Popović, D. Jovanović, Ðordje Popovic

引用次数: 2

Abstract

Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.

查看原文本刊更多论文

CD30 - tnf家族的头…或brentuximab vedotin的成功故事

霍奇金淋巴瘤和间变性大细胞淋巴瘤是细胞表面高表达CD30抗原的恶性肿瘤。这两种疾病通常都可以通过标准化疗治愈，但难治性疾病和复发是治疗问题。Brentuximab-vedotin是一种靶向CD30的标记单克隆抗体，被批准用于治疗自体干细胞移植后复发的霍奇金淋巴瘤和复发的间变性大细胞淋巴瘤。这是30年来首个被批准用于治疗霍奇金淋巴瘤的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archive of Oncology Medicine-Oncology

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： Archive of Oncology is an international oncology journal that publishes original research, editorials, review articles, case (clinical) reports, and news from oncology (medical, surgical, radiation), experimental oncology, cancer epidemiology, and prevention. Letters are also welcomed. Archive of Oncology is covered by Biomedicina Vojvodina, Biomedicina Serbica, Biomedicina Oncologica, EMBASE/Excerpta Medica, ExtraMED and SCOPUS.